Cassava Sciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 29
- Market Cap
- -
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT06390410
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects
- Conditions
- AbsorptionMetabolismExcretion
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06195319
- Locations
- 🇺🇸
Fortrea, Madison, Wisconsin, United States
Open-label Extension for Phase 3 Clinical Trials of Simufilam
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 1081
- Registration Number
- NCT05575076
- Locations
- 🇺🇸
Neurology Offices of South Florida, Boca Raton, Florida, United States
🇺🇸MDFirst Research, Chandler, Arizona, United States
🇺🇸CCT Research - Gilbert Neurology Partners, Gilbert, Arizona, United States
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05352763
- Locations
- 🇺🇸
Cognitive Clinical Trials, Papillion, Nebraska, United States
🇺🇸Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States
🇺🇸IMIC Research, Palmetto Bay, Florida, United States
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 1125
- Registration Number
- NCT05026177
- Locations
- 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸Clinical Research of Brandon, LLC, Brandon, Florida, United States
🇺🇸Quantum Laboratories, Deerfield Beach, Florida, United States
Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 804
- Registration Number
- NCT04994483
- Locations
- 🇺🇸
MDFirst Research, Chandler, Arizona, United States
🇺🇸CCT Research - Gilbert Neurology Partners, Gilbert, Arizona, United States
🇺🇸Xenoscience, Inc., Phoenix, Arizona, United States
Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04932655
- Locations
- 🇺🇸
Worldwide Clinical Trials Phase I Unit, San Antonio, Texas, United States
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Simufilam 100 mg oral tabletDrug: Placebo
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT04388254
- Locations
- 🇺🇸
Senior Adults Specialty Research, Austin, Texas, United States
🇺🇸IMIC, Inc., Palmetto Bay, Florida, United States
🇨🇦Ottawa Memory Clinic, Ottawa, Ontario, Canada
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Simufilam 50 mg oral tabletDrug: Placebo oral tabletDrug: Simufilam 100 mg tablet
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Cassava Sciences, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04079803
- Locations
- 🇺🇸
Cognitive Clinical Trials, Omaha, Nebraska, United States
🇺🇸Advanced Memory Research Institute, Toms River, New Jersey, United States
🇺🇸Optimus U, Miami, Florida, United States